Nuvation Bio Inc. (NUVB): A Bull Case Theory 

We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.'s share was trading at $3.2200 as of September 23rd.

Nuvation Bio (NUVB), founded in 2018 by David T. Hung, M.D., is an oncology biotech focused on next-generation kinase inhibitors targeting genetically defined cancers driven by aberrant kinase signaling. The company’s leadership team is heavily weighted toward technical expertise, with 70–80% of staff holding MD or PhD degrees and extensive experience...